

Summary of Amendment and Restatement to Code of Ethics and Business Conduct

On October 1, 2026, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) approved the amendment and restatement of the Company’s Code of Ethics and Business Conduct (the “Amended Code”). The Amended Code applies to all directors, officers and employees of the Company and to certain other covered persons as provided therein.

The amended provisions include:

- revisions to certain procedures for reviewing and resolving actual or potential conflicts of interest;
- standards for the use of artificial intelligence tools in alignment with the Company’s security, confidentiality, and ethical standards;
- enhanced compliance standards concerning clinical trials, field-based interactions, and patient advocacy;
- clarifications to securities-trading compliance requirements relating to material nonpublic information concerning other companies, and the addition of a prohibition on prediction-market trading; and
- clarifications regarding channels for reporting suspected violations of law, the Amended Code or other Company policies.

The Amended Code was effective upon adoption by the Board. The amendments did not result in any waiver, explicit or implicit, of any provision of the Company’s previous Code of Ethics and Business Conduct. The foregoing summary of the amendments is qualified in its entirety by reference to the full text of the Amended Code, which is available on the Company’s website at www.admabiologics.com under the “Investors – Governance – Governance Documents” section.